title: Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults.
abstract: In a study of older adults, first and second doses of 23-valent pneumococcal polysaccharide vaccine (PN23) induced IgG increases for all 8 vaccine serotypes tested. Participants (N=143, mean age 76 years) were re-enrolled to study antibody levels after ten years, and safety and immunogenicity of another PN23 dose. Ten years after first or second doses, mean IgG concentrations exceeded vaccine-naïve levels for 7 of 8 serotypes tested. Second and third doses administered at this time were generally well tolerated and were immunogenic, inducing similar postvaccination levels. Immunogenicity is preserved after multiple PN23 doses without evidence of a lower than expected immune response (i.e., without hyporesponsiveness).
authors.affiliation: Michael E. DeBakey VA Medical Center, Houston, TX, USA. Daniel.Musher@va.gov
authors.forename: Daniel M
authors.initials: DM
authors.lastname: Musher
authors.forename: Susan B
authors.initials: SB
authors.lastname: Manoff
authors.forename: Richard D
authors.initials: RD
authors.lastname: McFetridge
authors.forename: Charles L
authors.initials: CL
authors.lastname: Liss
authors.forename: Rocio D
authors.initials: RD
authors.lastname: Marchese
authors.forename: Jennifer
authors.initials: J
authors.lastname: Raab
authors.forename: Adriana M
authors.initials: AM
authors.lastname: Rueda
authors.forename: Monica L
authors.initials: ML
authors.lastname: Walker
authors.forename: Patricia A
authors.initials: PA
authors.lastname: Hoover
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000907:Antibodies, Bacterial / Q000097:blood* / Q000276:immunology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007115:Immunization Schedule; D007074:Immunoglobulin G / Q000097:blood* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D022242:Pneumococcal Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D011018:Pneumonia, Pneumococcal / Q000276:immunology / Q000517:prevention & control*; D013997:Time Factors
chemical_list: C414006:23-valent pneumococcal capsular polysaccharide vaccine; D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; D022242:Pneumococcal Vaccines